GENEDX HOLDINGS CORP.

NASDAQ: WGS (GeneDx Holdings Corp.)

最近更新时间: 28 Mar, 6:09AM

94.34

-2.10 (-2.18%)

前收盘价格 96.44
收盘价格 97.33
成交量 557,891
平均成交量 (3个月) 1,039,573
市值 2,647,963,392
价格/销量 (P/S) 9.05
股市价格/股市净资产 (P/B) 11.76
52周波幅
8.53 (-90%) — 115.60 (22%)
利润日期 28 Apr 2025 - 2 May 2025
营业毛利率 -17.12%
营业利益率 (TTM) 10.98%
稀释每股收益 (EPS TTM) -1.94
季度收入增长率 (YOY) 66.60%
总债务/股东权益 (D/E MRQ) 47.37%
流动比率 (MRQ) 3.61
营业现金流 (OCF TTM) -28.50 M
杠杆自由现金流 (LFCF TTM) 1.11 M
资产报酬率 (ROA TTM) -3.20%
股东权益报酬率 (ROE TTM) -22.10%

市场趋势

短期 中期
行业 Health Information Services (US) 混合的 混合的
Health Information Services (全球的) 混合的 混合的
股票 GeneDx Holdings Corp. 看涨 看涨

AIStockmoo 评分

-0.5
分析师共识 1.5
内部交易活动 -1.5
价格波动 -4.5
技术平均移动指标 0.0
技术振荡指标 2.0
平均 -0.50

相关股票

股票 市值 DY P/E(TTM) P/B
WGS 3 B - - 11.76
HQY 8 B - 81.07 3.69
TEM 7 B - - 152.50
WAY 7 B - - 2.35
RCM 6 B - - 2.14
PRVA 3 B - 215.18 4.35

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.

部门 Healthcare
行业 Health Information Services
投资方式 Small Growth
内部持股比例 13.65%
机构持股比例 87.55%

所有权

姓名 日期 持有股份
Oracle Investment Management Inc 31 Dec 2024 1,023,468
Science & Technology Partners, L.P. 31 Dec 2024 401,000
Gagnon Securities Llc 31 Dec 2024 359,376
52周波幅
8.53 (-90%) — 115.60 (22%)
目标价格波幅
80.00 (-15%) — 118.00 (25%)
118.00 (TD Cowen, 25.08%) 购买
99.00 (4.94%)
80.00 (Goldman Sachs, -15.20%) 保留
平均值 99.00 (4.94%)
总计 1 购买, 1 保留
平均价格@调整类型 104.18
公司 日期 目标价格 调整类型 价格@调整类型
Goldman Sachs 19 Feb 2025 80.00 (-15.20%) 保留 111.31
TD Cowen 07 Jan 2025 118.00 (25.08%) 购买 97.04

该时间范围内无数据。

日期 类型 细节
03 Apr 2025 公告 GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication
20 Mar 2025 公告 GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Mar 2025 公告 Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies
04 Mar 2025 公告 GeneDx Expands Commercial Footprint for Exome and Genome Testing with Cerebral Palsy as a New Indication
24 Feb 2025 公告 Landmark Seqfirst-neo Study Showcases the Significant Impact of Genomic Testing in the NICU, Revealing Gaps in Current Protocols
18 Feb 2025 公告 GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
13 Feb 2025 公告 GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
12 Feb 2025 公告 GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
10 Feb 2025 公告 GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
28 Jan 2025 公告 GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
17 Jan 2025 公告 GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Jan 2025 公告 GeneDx Announces Preliminary 2024 Financial Results
09 Jan 2025 公告 GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
08 Jan 2025 公告 GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票